| 1. |
An analysis of a multinational, randomized, double-blind, placebo-controlled phase 3 trial of sunitinib in patients with advanced, well-differentiated pancreatic neuroendocrine tumors. |
 |
Raymond E; Dahan L; Raoul, JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; |
February 2011 |
New England Journal of Medicine |
| 2. |
Prognostic factors for progression-free and overall survival in patients with metastatic renal cell carcinoma |
rcc |
Patil S; Figlin RA; Hutson TE; Michaelson MD; Negrier Sp; Kim ST; Huang X; Motzer RJ
|
May 2010 |
Annals of Oncology |
| 3. |
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/ pharmacodynamic meta-analysis |
 |
Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ |
December 2009 |
Cancer Chemother Pharmacol |
| 4. |
Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma |
rcc |
Motzer RJ, Hutson TE, Tomczak P,
et al |
June 2009 |
J Clin Oncol |
| 5. |
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. |
rcc |
Cella D, Li JZ, Cappelleri JC, et al |
August 2008 |
J Clin Oncol |
| 6. |
Temsirolimus, Interferon Alfa, or Both for Advanced Renal Cell Carcinoma |
rcc |
Hudes G; Carducci M; Tomczak P |
May 2007 |
New England Journal of Medicine |
| 7. |
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma |
rcc |
Motzer RJ, Hutson TE, Tomczak P,et al |
January 2007 |
N Engl J Med |
| 8. |
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial |
gist |
Demetri GD, van Oosterom AT, Garrett CR, et al |
October 2006 |
Lancet |
| 9. |
Sunitinib in patients with metastatic renal cell carcinoma |
rcc |
Motzer RJ, Rini BI, Bukowski RM, et al |
June 2006 |
JAMA |
| 10. |
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma |
rcc |
Michaelson MD, Redman BG, Motzer RJ, et al |
January 2006 |
J Clin Oncol |
| 11. |
Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma |
rcc |
Mekhail TM; Abou-Jawde RM; BouMerhi G |
February 2005 |
Journal of Clinical Oncology |
| 12. |
Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma |
rcc |
Motzer RJ; Bacik J; Murphy BA |
January 2002 |
Journal of Clinical Oncology |
